EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, HALO: Halozyme Therapeutic

06 Nov 25 17:20
LAST:

68.39

CHANGE:
 0.09		OPEN:
68.30		HIGH:
70.50		ASK:
11.45		VOLUME:
2.33M
CHG(%):
0.13		PREV:
68.30		LOW:
67.40		BID:
8.75		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 2568.3070.5067.4068.392.33M
05 Nov 2568.3170.4967.8068.301.51M
04 Nov 2567.6469.9365.0068.052.4M
03 Nov 2565.9866.3864.7266.202.75M
31 Oct 2564.1065.4963.8465.191.41M
30 Oct 2565.5166.2463.9564.631.79M
29 Oct 2565.7466.9764.9565.261.5M
28 Oct 2565.6566.2564.5565.40958.8K
27 Oct 2566.8066.9965.5665.851.34M
24 Oct 2566.9967.2866.1166.15994.2K

COMPANY PROFILE

Name:Halozyme Therapeutic
About:Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:12390 El Camino Real, San Diego, CA, United States, 92130
Website:https://halozyme.com
CUSIP:40637H109
CIK:0001159036
ISIN:US40637H1095
FIGI:BBG000CZ8W54
LEI:529900242I3SV9AGM753

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:14.92 
Forward P/E:13.47 
PEG Ratio:0.17 
Price to Sales:6.47 
Price to Book:23.04 
Profit Margin:0.47 
Operating Margin:0.62 
Return on Assets:0.21 
Return on Equity:1.79 
EPS Ratio:4.37 
Revenue:1.179B 
EBITDA:764.4M 
Shares:116.97M 
Market Cap:7.999B 

TECHNICAL INDICATORS

MA5:67.231.7%
MA10:66.343.1%
MA20:66.293.2%
MA50:70.753.5%
MA100:65.314.7%
MA200:61.8910.5%
STO9:64.05
STO14:64.05
RSI14:57.38
MTM14:1.92
ROC14:0.03 
ATR:2.06 
Week High:70.503.1%
Week Low:63.847.1%
Month High:70.503.1%
Month Low:63.7810.5%
Year High:79.5016.2%
Year Low:42.0162.8%